Other languages Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
77.19 ^USD	-0.08%		-4.46%	+0.04%

May. 30	Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference	CI
May. 29	Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MAURICEFLEX SYSTEM AT THE ANNUAL ASMS CONFERENCE	May. 31
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES	May. 31
BIO-TECHNE CORPORATION - SCALEREADY ANNOUNCES $20 MILLION G-REX GRANT PROGRAM FOR THE ADVANCEMENT OF CELL AND GENE THERAPY DEVELOPMENT AND MANUFACTURING	May. 30
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE	May. 30
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference	May. 30
Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM	May. 29
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing	May. 29
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE	May. 23
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY	May. 22
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration	May. 22
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target	May. 22
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing	May. 16
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM	May. 14
Ex-dividend day	May. 09	FA
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024	May. 08
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating	May. 06
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	May. 02
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	May. 02
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	May. 02
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	May. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Bio-Techne Corporation

Equities

TECH

US09073M1045

Other languages

Filters